{
  "pmcid": "11848516",
  "sha256": "5d54363821583722419c7159961c88bed403f9062380a3489dbebd0b26ae6db3",
  "timestamp_utc": "2025-11-09T15:24:46.263008+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.038790593505045,
    "reading_ease": 16.44105263157894,
    "word_count": 235
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A dual-centre RCT of patients assigned to receive either enoxaparin or normal saline after liver transplantation was conducted."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A dual-centre RCT of patients assigned to receive either enoxaparin or normal saline after liver transplantation was conducted."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "patients assigned to receive either enoxaparin or normal saline after liver transplantation"
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim of this study was to evaluate the efficacy and safety of prophylactic anticoagulation in patients undergoing deceased-donor liver transplantation."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary efficacy outcome was the incidence of venous thrombosis (portal vein thrombosis and deep vein thrombosis) and the primary safety outcome was the incidence of major bleeding."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 462 patients were recruited."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the intention-to-treat analysis, 89 patients (19.3%) experienced venous thrombosis and 141 patients (30.5%) experienced major bleeding within 90 days after transplantation."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Subgroup analysis revealed that anticoagulation was associated with a lower risk of deep vein thrombosis in hepatocellular carcinoma patients (HR 0.44 (95% c.i. 0.23 to 0.86), P = 0.016)"
      },
      "Harms": {
        "score": 1,
        "evidence": "The anticoagulant group demonstrated a markedly elevated incidence of major bleeding (35.5% versus 25.5%, P = 0.020)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Registration number: ChiCTR2000032441 ( www.chictr.org.cn )."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}